Journal profile · Neurosciences
Neurobiology of Disease
ISSN 0969-9961 · eISSN 1095-953X · Academic Press Inc. · ENGLAND · Bimonthly · Founded 1994
Neurobiology of Disease: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 5.89; fully open access; APC about USD 4,060; median 76 days to acceptance (130 articles, last 24 months); community-reported acceptance: fairly hard; 455 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Neurobiology of Disease is published by Academic Press Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Neuroscience and Neuropharmacology Research, Alzheimer's disease research and treatments and Parkinson's Disease Mechanisms and Treatments, together about 30.4% of its articles. Its main subfields are Neurology and Cellular and Molecular Neuroscience. (generated from OpenAlex topic counts and CAS ranking data)
Neurobiology of Disease is a major international open access journal at the interface between basic and clinical neuroscience. The journal provides a forum for the publication of top quality research or review papers on: molecular and cellular definitions of disease mechanisms, the neural systems and underpinning behavioral disorders, the genetics of inherited neurological and psychiatric diseases, nervous system aging, and findings relevant to the development of new therapies whether those are informative about the neurobiology of the considered condition. Neurobiology of Disease also welcomes manuscripts reporting negative results. Negative data and refutations are important to foster critical mind and scientific debate around important neurobiological questions. Authors must provide solid arguments to the Editors of the paramount importance of their observations. Validation of putative therapeutics without gaining significant new knowledge is not appropriate for Neurobiology of Disease. Similarly, articles with a narrowly focused application of a single technique, such as neuroimaging or ‘omics, are better suited for publication in specialized, methodologically focused journals. For instance, neuroimaging studies that do not incorporate molecular or cellular investigation fall outside the journal’s remit.
From the journal's Aims & Scope
Research area (LetPub): Neurosciences
Editor-in-chief Erwan BezardPublisher website
Editorial board by country: 13 in mainland China (about 9%); most named United States 67, Italy 19, Mainland China 13, France 9, Australia 9 (146 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neuroscience and Neuropharmacology ResearchNeuroscience11.9%
- Alzheimer's disease research and treatmentsMedicine9.3%
- Parkinson's Disease Mechanisms and TreatmentsMedicine9.2%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience6.7%
- Genetic Neurodegenerative DiseasesNeuroscience6.6%
- Neurological disorders and treatmentsMedicine5.9%
- Mitochondrial Function and PathologyBiochemistry, Genetics and Molecular Biology5.1%
- Neurogenesis and neuroplasticity mechanismsNeuroscience4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Neurosciences | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Neurosciences | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Neurosciences | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.89LetPub ·
- Impact factor (publisher)
- 6Publisher website ·
- CiteScore 2026-06
- 9.5LetPub ·
- CiteScore (publisher)
- 9.5Publisher website ·
- SJR 2026-06
- 2.16LetPub ·
- SNIP 2026-06
- 1.34LetPub ·
- h-index
- 151LetPub ·
- h-index
- 228OpenAlex ·
- i10-index
- 5,531OpenAlex ·
- 2-year mean citedness
- 5.18OpenAlex ·
- Self-citation rate
- 3.3%LetPub ·
- Share of gold OA articles
- 99.81%LetPub ·
Volume
- Articles per year
- 393LetPub ·
Articles by year OpenAlex count · 7,382 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 356 | 356 | 174 |
| 2025 | 455 | 455 | 1,908 |
| 2024 | 359 | 359 | 3,981 |
| 2023 | 379 | 379 | 7,576 |
| 2022 | 276 | 276 | 8,398 |
| 2021 | 274 | 274 | 7,914 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
76 daysMedian, submission to acceptance · P25–P75 46 days – 108 days
- Acceptance to online
- median 2 days (130 articles)
- Submission to online
- median 79 days
- Sample
- 130 articles with submission and acceptance dates (907 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–6 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
- Submission to first decision
- 1 daysPublisher website ·
- First decision after review
- 29 daysPublisher website ·
- Submission to acceptance
- 86 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,060 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 4,180 / EUR 3,910 / GBP 3,350 / JPY 518,450 | — | — | |
| Publisher website | USD 4,060 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Abstract
- ≤ 250 words
Article types accepted3
- discussion papers3. Discussion Papers: Discussion papers present an author's views and analysis of a specific topic, often based on existing research, without conducting origina…Length not stated
- research papers1. Research Papers: Full-length research papers will be considered for publication provided that they adhere to Neurobiology of Disease’s quality control requir…Length not stated
- review papers2. Review Papers: Review papers provide an in-depth review of a topic of interest to Neurobiology of Disease’s broad readership.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Academic Press Inc.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1994
- ISSN
- 0969-9961
- Electronic ISSN
- 1095-953X
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Neurobiology of Disease
What CAS zone is Neurobiology of Disease in?
In the 2025 upgraded edition of the CAS Journal Ranking, Neurobiology of Disease is in Zone 2 of Medicine, and in Zone 2 of the minor category Neurosciences; it is a Top journal. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Neurobiology of Disease?
The latest impact factor listed by LetPub is 5.89; CiteScore 9.5, h-index 228.
How long does peer review take at Neurobiology of Disease?
Based on the dates recorded on 130 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 76 days (interquartile range 46–108 days); authors report an average review time of 3–6 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Neurobiology of Disease based?
Of the 146 board members whose country the journal's board page names, 13 (about 9%) are in mainland China; the countries named most often are United States (67), Italy (19) and Mainland China (13). Counted from the institutions listed on the board page; for reference only.
Which databases index Neurobiology of Disease?
According to LetPub and DOAJ records, Neurobiology of Disease is indexed in SCIE, Scopus and DOAJ.
Is Neurobiology of Disease open access, and what is the APC?
Neurobiology of Disease is a fully open-access journal. APC about USD 4,060.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .